| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/01/2005 | US6849261 CD4-independent HIV envelope proteins as vaccines and therapeutics |
| 02/01/2005 | US6849260 Methods and compositions for treating IgE-related disease using NNT-1 inhibitors |
| 02/01/2005 | US6849257 Comprises catalytic or stoichiometric lipid removal, wherein proteins and/or polypeptides (lysosoymal acid lipase) target receptors in and/or on the cell which lead to uptake into the lysosome |
| 02/01/2005 | US6849254 Combination therapy of interferon-alfa and ribavirin in association with Vitamin E and Vitamin C to ameliorate ribavirin-related hemolysis |
| 02/01/2005 | CA2325351C Non-stochastic generation of genetic vaccines and enzymes |
| 02/01/2005 | CA2296080C Ophthalmic compositions containing galactomannan polymers and borate |
| 02/01/2005 | CA2182024C Method for preparing dry pharmaceutical forms, and resulting pharmaceutical compositions |
| 02/01/2005 | CA2094261C Polypeptide of a growth factor receptor family, application in the diagnosis and treatment of myeloproliferative diseases |
| 02/01/2005 | CA2083159C The combination of growth hormone and insulin-like growth factor-1 enhances growth |
| 01/29/2005 | CA2445420A1 Kinase and phosphatase assays |
| 01/27/2005 | WO2005008248A2 Diagnosis and treatment of cervical cancer |
| 01/27/2005 | WO2005007878A2 Method of modulating apoptosis and compositions thereof |
| 01/27/2005 | WO2005007859A2 RNA INTERFERENCE MEDIATED INHIBITION OF ACETYL-COA CARBOXYLASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/27/2005 | WO2005007855A2 RNA INTERFERENCE MEDIATED INHIBITION OF B7-H1 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/27/2005 | WO2005007854A2 Polycationic compositions for cellular delivery of polynucleotides |
| 01/27/2005 | WO2005007853A2 Inhibition of apoptosis-specific elf-5a (“eif-5a1”) with antisense oligonucleotides and sirnas as anti-inflammatory therapeutics |
| 01/27/2005 | WO2005007844A1 Method of screening for agents that modulate immunophilin/peptidylproline cis-trans isomerase (ppiase)-homer interaction |
| 01/27/2005 | WO2005007836A1 Regulatory t-cells containing galectins for the therapy and diagnosis of diseases |
| 01/27/2005 | WO2005007831A2 Compositions of protein mimetics and methods of using same against hiv-1, sars-cov and the like |
| 01/27/2005 | WO2005007820A2 Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity |
| 01/27/2005 | WO2005007811A2 Injection of bone marrow-derived cells and medium for angiogenesis |
| 01/27/2005 | WO2005007805A2 ANTISENSE ANTIVIRAL AGENT AND METHOD FOR TREATING ssRNA VIRAL INFECTION |
| 01/27/2005 | WO2005007804A2 Anthrax conjugate vaccine and antibodies |
| 01/27/2005 | WO2005007686A1 Rna binding peptide |
| 01/27/2005 | WO2005007684A1 Small molecule peptide to bind trap and their medicinal use |
| 01/27/2005 | WO2005007683A1 Antigen epitopes of the regulatory protein of virulence factor in staphylococcus aureus and their mimotopes and use |
| 01/27/2005 | WO2005007680A1 Arginine/lysine-enriched peptides |
| 01/27/2005 | WO2005007676A2 Glycopeptides for the treatment of als and other metabolic and autoimmune disorders |
| 01/27/2005 | WO2005007675A2 TRIAZOLE ϵ-AMINO ACIDS |
| 01/27/2005 | WO2005007654A1 Peptido-mimetic compounds containing rgd sequence useful as integrin inhibitors; and intermediates thereof |
| 01/27/2005 | WO2005007640A1 Preventive or therapeutic composition for viral infectious disease |
| 01/27/2005 | WO2005007199A1 COMPOUNDS AND METHODS FOR DOWNREGULATING THE EFFECTS OF TGF-β |
| 01/27/2005 | WO2005007193A2 Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor |
| 01/27/2005 | WO2005007187A1 Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment |
| 01/27/2005 | WO2005007186A1 Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin |
| 01/27/2005 | WO2005007185A2 Formulation for a protein pharmaceutical without added human serum albumin (hsa) |
| 01/27/2005 | WO2005007184A2 Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells |
| 01/27/2005 | WO2005007183A2 Treatment of anemia |
| 01/27/2005 | WO2005007177A1 Pharmaceutical agent against stomach ulcers |
| 01/27/2005 | WO2005007139A2 Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form |
| 01/27/2005 | WO2005007132A1 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
| 01/27/2005 | WO2005007122A2 Polymer stabilization |
| 01/27/2005 | WO2005007121A2 Mutant interleukin-2(il-2) polypeptides |
| 01/27/2005 | WO2005007118A2 Treatment or prevention of damage due to radiation exposure |
| 01/27/2005 | WO2005007108A2 Asymmetric disulfides and methods of using same |
| 01/27/2005 | WO2005007086A2 A method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
| 01/27/2005 | WO2005007079A2 Inactivators and bivalent inhibitors of glyoxalase i and methods of inhibiting tumor growth |
| 01/27/2005 | WO2005007078A2 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (sars) |
| 01/27/2005 | WO2005007072A2 Methods and pharmaceutical compositions for healing wounds |
| 01/27/2005 | WO2005007069A2 Soft gel formulations for saquinavir |
| 01/27/2005 | WO2005006890A2 Foods, beverages, condiments, spices and salad dressings with specialized supplements |
| 01/27/2005 | WO2004105785A3 Use of pam |
| 01/27/2005 | WO2004104005A3 Immunosuppressive effects of pteridine derivatives |
| 01/27/2005 | WO2004096846A3 Nogo-b, a regulator of endothelial cell function and vessel remodeling |
| 01/27/2005 | WO2004087046A3 TREATMENT OR PREVENTION OF cGMP-DEPENDENT PATHOPHYSIOLOGY WITH A MUTANT VARIANT OF SOLUBLE GUANYLYL CYCLASE |
| 01/27/2005 | WO2004084950A3 Cell targeting methods and compositions |
| 01/27/2005 | WO2004084927A3 Compositions for inducing of immunotolerance |
| 01/27/2005 | WO2004071218A3 Preparation and food product comprising an active phytase |
| 01/27/2005 | WO2004065411A3 Peptides |
| 01/27/2005 | WO2004064740A3 Sperm specific lysozyme-like proteins |
| 01/27/2005 | WO2004063222A3 Novel preadipocyte factor-1-like polypeptides |
| 01/27/2005 | WO2004060041A3 Kim-1 antagonists and use to modulate immune system |
| 01/27/2005 | WO2004043381A3 Compositions and methods for prolonging survival of platelets |
| 01/27/2005 | WO2004024756A3 Orthopoxvirus antigens and use thereof |
| 01/27/2005 | WO2003090687A3 Using heat shock proteins to increase immune response |
| 01/27/2005 | WO2003087374A9 Derivatives of the il-2 receptor gamma chain, their production and use. |
| 01/27/2005 | WO2003080807A3 Compositions and methods for suppressing eukaryotic gene expression |
| 01/27/2005 | WO2003076565A3 Methods of using 46828, a human acyl-coa synthetase |
| 01/27/2005 | WO2003072600A3 Methods of screening molecular libraries for active molecules that restore the function of target proteins and peptides that restore the function of mutant p53 |
| 01/27/2005 | WO2003057826A3 SOLUBLE GLcNAC PHOSPHOTRANSFERASE |
| 01/27/2005 | WO2003031594A3 Nucleotide and amino acid sequences relating to respiratory diseases and obesity |
| 01/27/2005 | WO2002087554B1 Ef-tu binding agent as antibacterial agent |
| 01/27/2005 | US20050020824 Testis-specific receptor |
| 01/27/2005 | US20050020817 Nucleotide sequences coding tumor marker protein for use as tools in detection, prevention a nd treatment of cell proliferative disorders |
| 01/27/2005 | US20050020816 Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc-globulin and a Gc-globulin medicinal product |
| 01/27/2005 | US20050020813 Streptococcus pneumoniae proteins and nucleic acids |
| 01/27/2005 | US20050020810 Peptides which target tumor and endothelial cells, compositions and uses thereof |
| 01/27/2005 | US20050020647 Compositions comprising epothilones and their use for the treatment of carcinoid syndrome |
| 01/27/2005 | US20050020547 Compounds for the treatment of female sexual dysfunction |
| 01/27/2005 | US20050020531 Systemic carnitine deficiency gene and uses thereof |
| 01/27/2005 | US20050020530 Treatment of parkinson's disease with oligonucleotides |
| 01/27/2005 | US20050020529 Delivery construct for antisense nucleic acids and methods of use |
| 01/27/2005 | US20050020528 Polynucleotide sequence coding hybrid protein; antiinflammatory agents; aids therapy; autoimmune disease |
| 01/27/2005 | US20050020525 first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence chemically modified so that it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; pharmaceutical use such as viricide |
| 01/27/2005 | US20050020523 Modified antisense nucleotides complementary to a section of the human haras gene |
| 01/27/2005 | US20050020522 Induce mitrosis and smooth muscle proliferation; administering to cell or tissue a polynucleotide which codes endothelial growth factor |
| 01/27/2005 | US20050020521 In vivo gene silencing by chemically modified and stable siRNA |
| 01/27/2005 | US20050020519 Increase concentration of peptide; controlling glucose uptake into cells; adjust metabolism; stimulate cell proliferation; reduce apoptosis; moderate gene expression' |
| 01/27/2005 | US20050020504 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 01/27/2005 | US20050020503 Hepatitis C inhibitor compounds |
| 01/27/2005 | US20050020502 Sincalide formulations |
| 01/27/2005 | US20050020500 Glycosaminoglycan-polypeptide complex; antiarthritic agents |
| 01/27/2005 | US20050020499 Methods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method |
| 01/27/2005 | US20050020498 Apo-2 ligand/trail formulations |
| 01/27/2005 | US20050020497 Mammalian glycoprotein hormone-1 |
| 01/27/2005 | US20050020496 Diagnosis, hormone replacement therapy for HIV positive females, gene therapy; metabolic disorders; antidiabetic, anticholesterol, hypoglycemic agents |
| 01/27/2005 | US20050020495 Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors |
| 01/27/2005 | US20050020494 Modified human growth hormone |
| 01/27/2005 | US20050020493 Immunology moderators; plypeptides; prevent inflammation of mucous membrane |
| 01/27/2005 | US20050020492 Melanin-concentrating hormone analogs |